对晚发性FGR中的肝动脉缓冲反应的洞察
Aziz Kından1, Can Ozan Ulusoy1, Aykut Kından2
1Department of Perinatology, Ankara Etlik City Hospital, Ankara 06170, Türkiye.
Journal of clinical medicine
|December 11, 2025
概括
胎儿肝动脉 (HA) 的多普勒超声波可以识别胎儿生长限制 (FGR) 的胎儿. 在FGR胎儿中增加HA峰缩速度 (PSV) 可能预测新生儿不良后果.
科学领域:
- 周围生理学 周围生理学
- 胎儿医学 胎儿医学
- 诊断性的超声波检查
背景情况:
- 胎儿生长限制 (FGR) 是围产期发病率和死亡率的主要原因之一.
- 在FGR中评估胎儿福祉需要可靠的多普勒参数.
- 肝动脉 (HA) 在胎儿的循环适应中发挥作用.
研究的目的:
- 为了评估肝动脉 (HA) 多普勒参数在胎儿与FGR.
- 调查HA多普勒参数与新生儿不良结果 (CANO) 之间的关系.
主要方法:
- 在妊娠34-37周之间对108例怀孕 (54例FGR,54例对照) 的前性队列研究.
- 记录了HA的多普勒指数,动脉 (UA),中脑动脉 (MCA) 和子宫动脉.
- 使用后勤回归和ROC分析来确定FGR和CANO的预测因素.
主要成果:
- FGR胎儿显示出明显更高的HA脉动性指数 (PI),缩/透缩比和最大缩速度 (PSV) (p <0.05).
- HA-PI与FGR独立相关 (aOR为1.74).
- HA-PSV是CANO的唯一独立预测因子 (aOR 1.05),具有中度的区分能力 (AUC 0.703).
结论:
- 在FGR中HA-PSV升高表明,在低氧压力下维持肝 perfusion 的适应性反应.
- 增加HA-PI可能表明正在发展的微血管耐药性.
- 哈多普勒评估可以补充胎儿福祉评估,并识别高风险胎儿,特别是在晚期发病的FGR.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
200
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
200
Pharmacokinetics in Pediatric Patients: Drug Metabolism
174
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
174
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
236
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
236
Fetal Circulation
2.4K
Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
2.4K
Pharmacokinetics in Pediatric Patients: Drug Distribution
240
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
240


